STAT

Opinion: Diversity in the biopharma industry makes dollars and sense

Biotech CEOs who want to continue receiving investments from some of the largest players in the financial services sector should hear and heed their messages about diversity.
State Street Global Advisors erected a statue of a fearless girl staring down Wall Street's rampaging bull last March in New York. As it went up, the firm called on its 3,500 portfolio companies to increase the representation of women at the board level.

When the European Union made a fresh push for diversity quotas on corporate boards last year, many market watchers dismissed the move as political correctness run amok. The U.S. financial sector would never go along, they predicted, as Wall Street has never been a place for social experiments.

It is turning out that the business case for diversity is proving too powerful to dismiss. A series of recent studies examining diversity and financial performance have fueled growing insistence among big-name private equity firms, pension funds, and money

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks